Table 7 Improved predictive performance using only selected features in decision trees, random forests, and support vector machines for healthy controls (HCs) versus rheumatoid arthritis (RA) patients and osteoarthritis (OA) versus RA patients

HC v.s. RA

 DT

0.84 (0.80–0.87)

0.92 (0.88–0.95)

0.80 (0.76–0.85)

0.73 (0.67–0.80)

0.93 (0.89–0.97)

0.86 (0.82–0.89)

IgM anti-HPT⁷⁸⁻¹⁰⁸ HNE

IgG anti-THRB^328−345

 RF

0.87 (0.85–0.90)

0.91 (0.87–0.95)

0.85 (0.82–0.88)

0.81 (0.76–0.87)

0.93 (0.91–0.96)

0.92 (0.90–0.95)

IgM anti-HPT⁷⁸⁻¹⁰⁸ HNE

IgM anti-HPT⁷⁸⁻¹⁰⁸

IgG anti-HPT⁷⁸⁻¹⁰⁸

IgG anti-THRB^328−345

HNE adducts

 SVM

0.71 (0.62–0.80)

0.97 (0.91–1.00)

0.56 (0.42–0.70)

0.42 (0.27–0.58)

0.98 (0.95–1.00)

0.82 (0.75–0.89)

IgM anti-HPT⁷⁸⁻¹⁰⁸ HNE

IgG anti-HPT⁷⁸⁻¹⁰⁸ HNE

IgM anti IGKC²⁻¹⁹

IgM anti-CFAH^1121−1230 HNE

OA v.s. RA

 DT

0.81 (0.75–0.87)

0.94 (0.89–0.98)

0.82 (0.76–0.89)

0.74 (0.62–0.83)

0.93 (0.88–0.98)

0.84 (0.79–0.89)

IgM anti-HPT⁷⁸⁻¹⁰⁸ HNE IgG anti-THRB^328−345 IgG anti-IGKC²⁻¹⁹

 RF

0.85 (0.81–0.89)

0.87 (0.82–0.91)

0.87 (0.82–0.92)

0.88 (0.79–0.97)

0.79 (0.71–0.87)

0.92 (0.88–0.96)

IgM anti-HPT⁷⁸⁻¹⁰⁸ HNE IgG anti-HPT⁷⁸⁻¹⁰⁸ HNE IgG anti-IGKC²⁻¹⁹ IgM anti-CFAH^1121−1230 HNE

 SVM

0.68 (0.61–0.76)

0.68 (0.61–0.76)

0.81 (0.75–0.86)

0.53 (0.31–0.66)

0.94 (0.89–0.98)

0.88 (0.83–0.93)

IgM anti-HPT⁷⁸⁻¹⁰⁸ HNE IgG anti-THRB^328−345